Lead immunotherapy candidate asunercept is in clinical development for the treatment of solid tumors, malignant hematological diseases, and COVID-19. It has been shown to prolong overall survival in a phase II trial in recurrent glioblastoma – the most frequent and aggressive brain tumor – and has demonstrated hematological improvements in a phase I trial in myelodysplastic syndromes (MDS) – a stem cell disorder that can lead to severe anemia. Asunercept is currently being evaluated in a phase II trial in patients with COVID-19.
Apogenix has also developed a proprietary technology platform for the construction of novel TNF superfamily receptor agonists which allows the generation of hexavalent molecules (HERA-ligands) and bispecific agents. These receptor agonists stimulate and enhance the anti-tumor immune response and have the potential for broad application in oncology.
Apogenix at a glance:
|Field of Activity
||Apogenix develops innovative immunotherapeutics for the treatment of cancer and viral infections, such as COVID-19. The company has built a promising pipeline of drug candidates that target different TNFSF-dependent signaling pathways, thereby restoring the anti-tumor immune response in cancer patients and reducing lymphopenia and inflammatory cell death in patients with viral infections.|
|Products/Services||Asunercept: CD95 ligand inhibitor asunercept is in clinical development for the treatment of glioblastoma, MDS, and COVID-19. Preclinical studies in other solid tumors demonstrate the potential of asunercept in a broad range of oncology indications.
Technology Platform: Apogenix’ novel TNF superfamily receptor agonists (HERA-ligands and bispecific agents) are being developed for the treatment of hematologic and solid tumors. They have shown strong anti-tumor efficacy in vitro and in vivo, with a benign safety profile.
|Technology and Unique Selling Point||Apogenix has developed a proprietary technology platform for the construction of novel receptor agonists that target different TNFSF-dependent signaling pathways, which play a crucial role in the regulation of the immune response. These HERA-ligands and bispecific agents overcome the structural limitations of other biologics targeting TNFSF pathways, such as antibodies.|
|Date of Incorporation/
Number of Employees
|Address||Im Neuenheimer Feld 584
|Telephone/Telefax||+49 6221 58608-0/-10|
- Apogenix erhält 20,7 Mio. EUR Förderung im Kampf gegen Covid-19
- „MDS ist eine Indikation mit hohem medizinischen Bedarf“
- Apogenix erhält europäisches Patent für APG101
- Apogenix erhält 3 Mio. EUR BMBF-Förderung
- Apogenix erhält Meilensteinzahlung von CANbridge
- R-Biopharm und Apogenix schließen Kooperation
- Apogenix: Signifikanter Überlebensvorteil durch APG101